CANCER RESEARCH: Why Some Leukemia Cells Resist STI-571

摘要: The antileukemia drug known as Gleevec or STI-571 has been heralded the vanguard of a new generation cancer chemotherapy agents, designed specifically to counteract biochemical changes that make cells cancerous. Yet shares an unfortunate characteristic with older, conventional drugs. Patients advanced disease often relapse; their tumor become resistant and eventually grow out control. Results published online by Science on 21 June (www.sciencexpress.org) now explain why this happens in STI-571, perhaps point way improved therapies.